Casdin Capital

Casdin Capital is a New York-based venture capital firm specializing in life sciences and healthcare investments. The firm focuses on sectors such as healthcare, biotechnology, synthetic biology, and technology, leveraging advancements in molecular information to drive innovation. Casdin Capital partners with companies to create value and open new opportunities, emphasizing patience, persistence, and strong relationships.

The firm's investment strategy targets significant markets, investing in exceptional ideas and teams while maintaining a disciplined and principled approach. Casdin Capital's expertise spans various stages of company development, including seed, early stage, growth, late stage, and pre-IPO investments. The firm is known for its consistent, disciplined, engaged, principled, farsighted, knowledgeable, and reflective approach to investing.

Casdin Capital's portfolio includes notable companies such as 23andMe, 4D Molecular Therapeutics, 908 Devices, A2 Biotherapeutics, AbSci, Adaptive Biotechnologies, Affinia Therapeutics, Alector, Aledade, and AmplifyBio. These investments reflect the firm's commitment to advancing the life sciences revolution and supporting innovative solutions in healthcare and biotechnology.